BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol 2015; 7(12): 1632-1651 [PMID: 26140083 DOI: 10.4254/wjh.v7.i12.1632] [Cited by in CrossRef: 120] [Cited by in F6Publishing: 107] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Winkelmann MT, Archid R, Gohla G, Hefferman G, Kübler J, Weiss J, Clasen S, Nikolaou K, Nadalin S, Hoffmann R. MRI-guided percutaneous thermoablation in combination with hepatic resection as parenchyma-sparing approach in patients with primary and secondary hepatic malignancies: single center long-term experience. Cancer Imaging 2020;20:37. [PMID: 32460898 DOI: 10.1186/s40644-020-00316-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Chen R, Gao Z, Wu X, Campbell JL, Zhang P, Chen B. Hepatocellular carcinoma presenting as thoracic spinal canal metastasis with no clinical primary foci: A report of a rare case and review of the literature. Oncol Lett 2015;10:2333-6. [PMID: 26622846 DOI: 10.3892/ol.2015.3569] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
3 Zayed SA, Zahran NM, Khorshied MM, Abdel-Aziz AO, Mahmoud O, Morsy SA, Shousha HI, Elbaz TM, Nabeel MM, Harb ARK. Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma. J Med Virol. 2019;91:1537-1544. [PMID: 30945308 DOI: 10.1002/jmv.25476] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Schneller D, Angel P; Division of Signal Transduction and Growth Control, DKFZ-ZMBH Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany, Division of Signal Transduction and Growth Control, DKFZ-ZMBH Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany. Cellular Origin of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 1-28. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wang F, Wang J, Ju L, Chen L, Cai W, Yang J. Diagnostic and prognostic potential of serum miR-132/212 cluster in patients with hepatocellular carcinoma.Ann Clin Biochem. 2018;55:576-582. [PMID: 29357677 DOI: 10.1177/0004563218755815] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
6 Reinhardt M, Brandmaier P, Seider D, Kolesnik M, Jenniskens S, Sequeiros RB, Eibisberger M, Voglreiter P, Flanagan R, Mariappan P, Busse H, Moche M; ClinicIMPPACT Study Group. A prospective development study of software-guided radio-frequency ablation of primary and secondary liver tumors: Clinical intervention modelling, planning and proof for ablation cancer treatment (ClinicIMPPACT). Contemp Clin Trials Commun 2017;8:25-32. [PMID: 29696193 DOI: 10.1016/j.conctc.2017.08.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
7 Xu K, Watanabe-Galloway S, Rochling FA, Zhang J, Farazi PA, Peng H, Wang H, Luo J. Practice, Knowledge, and Barriers for Screening of Hepatocellular Carcinoma Among High-Risk Chinese Patients. Ann Glob Health 2017;83:281-92. [PMID: 28619403 DOI: 10.1016/j.aogh.2017.02.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Sakisaka M, Haruta M, Komohara Y, Umemoto S, Matsumura K, Ikeda T, Takeya M, Inomata Y, Nishimura Y, Senju S. Therapy of primary and metastatic liver cancer by human iPS cell-derived myeloid cells producing interferon-β. J Hepatobiliary Pancreat Sci 2017;24:109-19. [PMID: 28008721 DOI: 10.1002/jhbp.422] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
9 Waqar W, Asghar S, Manzoor S. Platelets' RNA as biomarker trove for differentiation of early-stage hepatocellular carcinoma from underlying cirrhotic nodules. PLoS One 2021;16:e0256739. [PMID: 34469466 DOI: 10.1371/journal.pone.0256739] [Reference Citation Analysis]
10 Li S, Jiang H, Yao Y, Pang W, Sun Q, Kuang L. Structure convolutional extreme learning machine and case-based shape template for HCC nucleus segmentation. Neurocomputing 2018;312:9-26. [DOI: 10.1016/j.neucom.2018.05.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sang Eun H, Seong Min K, Ho Jeong L, Vetrivel P, Venkatarame Gowda Saralamma V, Jeong Doo H, Eun Hee K, Sang Joon L, Gon Sup K. Scutellarein Induces Fas-Mediated Extrinsic Apoptosis and G2/M Cell Cycle Arrest in Hep3B Hepatocellular Carcinoma Cells. Nutrients 2019;11:E263. [PMID: 30682875 DOI: 10.3390/nu11020263] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
12 Zhu HX, Lu WJ, Zhu WP, Yu S. Comprehensive analysis of N6 -methyladenosine-related long non-coding RNAs for prognosis prediction in liver hepatocellular carcinoma. J Clin Lab Anal 2021;:e24071. [PMID: 34741346 DOI: 10.1002/jcla.24071] [Reference Citation Analysis]
13 da Silva EFG, Lima KG, Krause GC, Haute GV, Pedrazza L, Catarina AV, Gassen RB, de Souza Basso B, Dias HB, Luft C, Garcia MCR, Costa BP, Antunes GL, Basso LA, Donadio MVF, Machado P, de Oliveira JR. CPBMF65, a synthetic human uridine phosphorylase-1 inhibitor, reduces HepG2 cell proliferation through cell cycle arrest and senescence. Invest New Drugs 2020;38:1653-63. [DOI: 10.1007/s10637-020-00941-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lu M, Kong X, Wang H, Huang G, Ye C, He Z. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis. Oncotarget 2017;8:8775-84. [PMID: 28060739 DOI: 10.18632/oncotarget.14452] [Cited by in Crossref: 40] [Cited by in F6Publishing: 55] [Article Influence: 13.3] [Reference Citation Analysis]
15 Gibriel AA, Al-anany AM, Al-arab MAE, Azzazy HME. Investigating circulatory microRNA expression profiles in Egyptian patients infected with hepatitis C virus mediated hepatic disorders. Meta Gene 2020;26:100792. [DOI: 10.1016/j.mgene.2020.100792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
16 Zou W, Cheng J. MiR-887 Promotes the Progression of Hepatocellular Carcinoma via Targeting VHL. Technol Cancer Res Treat 2020;19:1533033820940425. [PMID: 32912113 DOI: 10.1177/1533033820940425] [Reference Citation Analysis]
17 Galanakis N, Kehagias E, Matthaiou N, Samonakis D, Tsetis D. Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. Hepat Oncol 2018;5:HEP07. [PMID: 31293775 DOI: 10.2217/hep-2018-0001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Guo J, Yang Y, Zhang J, Guo M, Xiang L, Yu S, Ping H, Zhuo L. microRNA‐448 inhibits stemness maintenance and self‐renewal of hepatocellular carcinoma stem cells through the MAGEA6‐mediated AMPK signaling pathway. J Cell Physiol 2019;234:23461-74. [DOI: 10.1002/jcp.28915] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
19 Ghousein A, Mosca N, Cartier F, Charpentier J, Dupuy JW, Raymond AA, Bioulac-Sage P, Grosset CF. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation. Liver Int 2020;40:240-51. [PMID: 31612616 DOI: 10.1111/liv.14276] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
20 Zekri AN, El-Sisi ER, Abdallah ZF, Ismail A, Barakat Barakat A. Gene expression profiling of circulating CD133+ cells of hepatocellular carcinoma patients associated with HCV infection. J Egypt Natl Canc Inst 2017;29:19-24. [PMID: 28258914 DOI: 10.1016/j.jnci.2016.12.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
21 Weigum S, Mcivor E, Munoz C, Feng R, Cantu T, Walsh K, Betancourt T. Targeted therapy of hepatocellular carcinoma with aptamer-functionalized biodegradable nanoparticles. J Nanopart Res 2016;18. [DOI: 10.1007/s11051-016-3633-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
22 Xu H, Tang Y, Zhao Y, Wang F, Gao X, Deng D, Gu Y. SPECT Imaging of Hepatocellular Carcinoma Detection by the GPC3 Receptor. Mol Pharm 2021;18:2082-90. [PMID: 33797932 DOI: 10.1021/acs.molpharmaceut.1c00060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Liu XF, Hao JL, Xie T, Pant OP, Lu CB, Lu CW, Zhou DD. The BRAF activated non-coding RNA: A pivotal long non-coding RNA in human malignancies. Cell Prolif 2018;51:e12449. [PMID: 29484737 DOI: 10.1111/cpr.12449] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
24 Sun W, Fu S, Wu S, Tu R. Growing Evidence of Exosomal MicroRNA-Related Metastasis of Hepatocellular Carcinoma. Biomed Res Int 2020;2020:4501454. [PMID: 33313314 DOI: 10.1155/2020/4501454] [Reference Citation Analysis]
25 Wu L, Liu S, Wei J, Li D, Liu X, Wang J, Wang L. Synthesis and biological evaluation of matrine derivatives as anti-hepatocellular cancer agents. Bioorg Med Chem Lett 2016;26:4267-71. [PMID: 27481558 DOI: 10.1016/j.bmcl.2016.07.045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
26 Hu P, Ke C, Guo X, Ren P, Tong Y, Luo S, He Y, Wei Z, Cheng B, Li R, Luo J, Meng Z. Both glypican-3/Wnt/β-catenin signaling pathway and autophagy contributed to the inhibitory effect of curcumin on hepatocellular carcinoma. Dig Liver Dis 2019;51:120-6. [PMID: 30001951 DOI: 10.1016/j.dld.2018.06.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 7.7] [Reference Citation Analysis]
27 Xing H, Qiu H, Ding X, Han J, Li Z, Wu H, Yan C, Li H, Han R, Zhang H, Li C, Wang M, Wu M, Shen F, Zheng Y, Yang T. Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma. Biomark Med 2019;13:545-55. [PMID: 31140827 DOI: 10.2217/bmm-2018-0414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
28 Li P, Fan H, He Q. Investigation of the clinical significance and prognostic value of microRNA-145 in human hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e13715. [PMID: 30572504 DOI: 10.1097/MD.0000000000013715] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
29 Aboubakr EM, Taye A, Aly OM, Gamal-Eldeen AM, El-Moselhy MA. Enhanced anticancer effect of Combretastatin A-4 phosphate when combined with vincristine in the treatment of hepatocellular carcinoma. Biomed Pharmacother 2017;89:36-46. [PMID: 28214686 DOI: 10.1016/j.biopha.2017.02.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
30 Jiang H, Zhao L, Chen Y, Sun L. A four-long noncoding RNA signature predicts survival of hepatocellular carcinoma patients. J Clin Lab Anal 2020;34:e23377. [PMID: 32474975 DOI: 10.1002/jcla.23377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Han Z, Feng W, Hu R, Ge Q, Ma W, Zhang W, Xu S, Zhan B, Zhang L, Sun X, Zhou X. RNA-seq profiling reveals PBMC RNA as a potential biomarker for hepatocellular carcinoma. Sci Rep 2021;11:17797. [PMID: 34493740 DOI: 10.1038/s41598-021-96952-x] [Reference Citation Analysis]
32 Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med 2016; 6(1): 21-36 [PMID: 26929917 DOI: 10.5493/wjem.v6.i1.21] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 15.0] [Reference Citation Analysis]
33 Zhong Y, Li Y, Song T, Zhang D. MiR-718 mediates the indirect interaction between lncRNA SEMA3B-AS1 and PTEN to regulate the proliferation of hepatocellular carcinoma cells. Physiol Genomics 2019;51:500-5. [PMID: 31251699 DOI: 10.1152/physiolgenomics.00019.2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
34 Abdelsameea E, Nada A, Omar N, Saleh SM, Naguib M, El-Ezawy HEM, Bakry L, Elsabaawy M. Urine Neutrophil Gelatinase-Associated Lipocalin a Possible Diagnostic Marker for Egyptian Hepatocellular Carcinoma Patients. Asian Pac J Cancer Prev 2020;21:2259-64. [PMID: 32856853 DOI: 10.31557/APJCP.2020.21.8.2259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Li G, Liu D, Cooper TK, Kimchi ET, Qi X, Avella DM, Li N, Yang QX, Kester M, Rountree CB, Kaifi JT, Cole DJ, Rockey DC, Schell TD, Staveley-O'Carroll KF. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. J Hepatol 2017;66:75-85. [PMID: 27520877 DOI: 10.1016/j.jhep.2016.07.044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
36 Yuan D, Chen Y, Li X, Li J, Zhao Y, Shen J, Du F, Kaboli PJ, Li M, Wu X, Ji H, Cho CH, Wen Q, Li W, Xiao Z, Chen B. Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis. Int J Biol Sci 2021;17:220-35. [PMID: 33390845 DOI: 10.7150/ijbs.50730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
37 Sastre J, Díaz-Beveridge R, García-Foncillas J, Guardeño R, López C, Pazo R, Rodriguez-Salas N, Salgado M, Salud A, Feliu J. Clinical guideline SEOM: hepatocellular carcinoma. Clin Transl Oncol 2015;17:988-95. [PMID: 26607931 DOI: 10.1007/s12094-015-1451-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
38 Ruan J, Zheng H, Rong X, Rong X, Zhang J, Fang W, Zhao P, Luo R. Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients. Mol Cancer 2016;15:17. [PMID: 26896959 DOI: 10.1186/s12943-016-0503-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
39 Kronenfeld JP, Goel N. An Analysis of Individual and Contextual-Level Disparities in Screening, Treatment, and Outcomes for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1209-19. [PMID: 34611524 DOI: 10.2147/JHC.S284430] [Reference Citation Analysis]
40 Masuda T, Beppu T, Okabe H, Nitta H, Imai K, Hayashi H, Chikamoto A, Yamamoto K, Ikeshima S, Kuramoto M, Shimada S, Baba H. Predictive factors of pathological vascular invasion in hepatocellular carcinoma within 3 cm and three nodules without radiological vascular invasion. Hepatol Res 2016;46:985-91. [PMID: 26670198 DOI: 10.1111/hepr.12637] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
41 Qian EN, Han SY, Ding SZ, Lv X. Expression and diagnostic value of CCT3 and IQGAP3 in hepatocellular carcinoma. Cancer Cell Int 2016;16:55. [PMID: 27390551 DOI: 10.1186/s12935-016-0332-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
42 Mohamed AA, El-toukhy N, Ghaith DM, Badawy I, Abdo SM, Elkadeem M, Mahrous MN, Abd-elsalam S. Talin-1 Gene Expression as a Tumor Marker in Hepatocellular Carcinoma Patients: A Pilot Study. TOBIOMJ 2020;10:15-22. [DOI: 10.2174/1875318302010010015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
43 Hagag NA, Ali YBM, Elsharawy AA, Talaat RM. Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression. J Gastrointest Cancer. 2020;51:234-241. [PMID: 31028536 DOI: 10.1007/s12029-019-00234-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
44 Lu H, Han M, Yuan X, Tursun K, Zhang Y, Li Y, Li Z, Feng S, Zhou L, Pan Z, Wang Q, Han K, Liu S, Cheng J. Role of IL-6-mediated expression of NS5ATP9 in autophagy of liver cancer cells. J Cell Physiol 2018;233:9312-9. [PMID: 29227529 DOI: 10.1002/jcp.26343] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
45 Mohankumar S, Patel T. Extracellular vesicle long noncoding RNA as potential biomarkers of liver cancer. Brief Funct Genomics 2016;15:249-56. [PMID: 26634812 DOI: 10.1093/bfgp/elv058] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 11.3] [Reference Citation Analysis]
46 Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML. The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma. Int J Mol Sci 2018;19:E1007. [PMID: 29597259 DOI: 10.3390/ijms19041007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
47 Zhou Y, Li K, Dai T, Wang H, Hua Z, Bian W, Wang H, Chen F, Ai X. Long non-coding RNA HCP5 functions as a sponge of miR-29b-3p and promotes cell growth and metastasis in hepatocellular carcinoma through upregulating DNMT3A. Aging (Albany NY) 2021;13:16267-86. [PMID: 34148029 DOI: 10.18632/aging.203155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. Int J Mol Sci 2020;21:E6757. [PMID: 32942580 DOI: 10.3390/ijms21186757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Tang JC, Feng YL, Guo T, Xie AY, Cai XJ. Circulating tumor DNA in hepatocellular carcinoma: Trends and challenges. Cell Biosci. 2016;6:32. [PMID: 27182434 DOI: 10.1186/s13578-016-0100-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
50 Lee W, Han HS, Ahn S, Yoon YS, Cho JY, Choi Y. Correlation between Resection Margin and Disease Recurrence with a Restricted Cubic Spline Model in Patients with Resected Hepatocellular Carcinoma. Dig Surg 2018;35:520-31. [PMID: 29342456 DOI: 10.1159/000485805] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
51 An HJ, Shin WY, Lee KY, Ahn SI. A comparison of the risk factors of intrahepatic recurrence, early recurrencen, and multiple recurrences after resection for single nodular hepatocellular carcinoma. Korean J Hepatobiliary Pancreat Surg 2015;19:89-97. [PMID: 26379729 DOI: 10.14701/kjhbps.2015.19.3.89] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
52 Zhao CC, Yu WW, Qi YJ, Xu LF, Wang ZR, Qiang YW, Ma F, Ma XL. Quantitative proteomic analysis reveals that Luks-PV exerts antitumor activity by regulating the key proteins and metabolic pathways in HepG2 cells. Anticancer Drugs 2020;31:223-30. [PMID: 31789624 DOI: 10.1097/CAD.0000000000000866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Mody K, Cleary SP. A Review of Circulating Tumor DNA in Hepatobiliary Malignancies. Front Oncol 2018;8:212. [PMID: 29942792 DOI: 10.3389/fonc.2018.00212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
54 Menegotto AB, Becker CDL, Cazella SC. Computer-aided diagnosis of hepatocellular carcinoma fusing imaging and structured health data. Health Inf Sci Syst 2021;9:20. [PMID: 33968399 DOI: 10.1007/s13755-021-00151-x] [Reference Citation Analysis]
55 Mao LH, Chen SY, Li XQ, Xu F, Lei J, Wang QL, Luo LY, Cao HY, Ge X, Ran T, Li X, Zou M, Zhou ZH, Wu XL, He S. LncRNA-LALR1 upregulates small nucleolar RNA SNORD72 to promote growth and invasion of hepatocellular carcinoma. Aging (Albany NY) 2020;12:4527-46. [PMID: 32160589 DOI: 10.18632/aging.102907] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
56 Qiao G, Xu H, Li C, Li X, Farooqi AA, Zhao Y, Liu X, Liu M, Stagos D, Lin X. Granulin A Synergizes with Cisplatin to Inhibit the Growth of Human Hepatocellular Carcinoma. Int J Mol Sci 2018;19:E3060. [PMID: 30301274 DOI: 10.3390/ijms19103060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
57 Yu J, Han J, Zhang J, Li G, Liu H, Cui X, Xu Y, Li T, Liu J, Wang C. The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis. Medicine (Baltimore) 2016;95:e4436. [PMID: 27495068 DOI: 10.1097/MD.0000000000004436] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 9.5] [Reference Citation Analysis]
58 印磊, 陈钟. Toll样受体4在肝细胞肝癌中的研究进展. 世界华人消化杂志 2016; 24(4): 535-541 [DOI: 10.11569/wcjd.v24.i4.535] [Reference Citation Analysis]
59 Han C, Jiang Y, Wang Z, Wang H. Natural killer cells involved in tumour immune escape of hepatocellular carcinomar. Int Immunopharmacol 2019;73:10-6. [PMID: 31078921 DOI: 10.1016/j.intimp.2019.04.057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
60 Zayed Mohamed N, Aly HF, Moneim El-Mezayen HA, El-Salamony HE. Effect of co-administration of Bee honey and some chemotherapeutic drugs on dissemination of hepatocellular carcinoma in rats. Toxicol Rep 2019;6:875-88. [PMID: 31516840 DOI: 10.1016/j.toxrep.2019.08.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
61 Ismail IT, Fiehn O, Elfert A, Helal M, Salama I, El-Said H. Sugar Alcohols Have a Key Role in Pathogenesis of Chronic Liver Disease and Hepatocellular Carcinoma in Whole Blood and Liver Tissues. Cancers (Basel) 2020;12:E484. [PMID: 32092943 DOI: 10.3390/cancers12020484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
62 Chen F, Wang H, Zhu J, Zhao R, Xue P, Zhang Q, Bud Nelson M, Qu W, Feng B, Pi J. Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs. Br J Cancer 2017;117:1495-506. [PMID: 28910823 DOI: 10.1038/bjc.2017.317] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
63 Shen Y, Bu L, Li R, Chen Z, Tian F, Lu N, Ge Q, Bai Y, Lu Z. Screening effective differential expression genes for hepatic carcinoma with metastasis in the peripheral blood mononuclear cells by RNA-seq. Oncotarget 2017;8:27976-89. [PMID: 28427195 DOI: 10.18632/oncotarget.15855] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
64 Yang F, Zhao J, Liu C, Mao Y, Mu J, Wei X, Jia J, Zhang S, Xin X, Tan J. Superb microvascular imaging technique in depicting vascularity in focal liver lesions: more hypervascular supply patterns were depicted in hepatocellular carcinoma. Cancer Imaging 2019;19:92. [PMID: 31888768 DOI: 10.1186/s40644-019-0277-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
65 Hou Y, Chen K, Liao R, Li Y, Yang H, Gong J. LINC01419-mediated epigenetic silencing of ZIC1 promotes metastasis in hepatocellular carcinoma through the PI3K/Akt signaling pathway. Lab Invest 2021;101:570-87. [PMID: 33772101 DOI: 10.1038/s41374-021-00539-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Fiorino S, Bacchi-Reggiani ML, Visani M, Acquaviva G, Fornelli A, Masetti M, Tura A, Grizzi F, Zanello M, Mastrangelo L, Lombardi R, Di Tommaso L, Bondi A, Sabbatani S, Domanico A, Fabbri C, Leandri P, Pession A, Jovine E, de Biase D. MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma. World J Gastroenterol 2016; 22(15): 3907-3936 [PMID: 27099435 DOI: 10.3748/wjg.v22.i15.3907] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
67 Ding K, Liao Y, Gong D, Zhao X, Ji W. Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+ cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma. Biochemical and Biophysical Research Communications 2018;502:194-201. [DOI: 10.1016/j.bbrc.2018.05.143] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
68 Zheng SL, Yip VS, Pedica F, Prachalias A, Quaglia A. Intrahepatic bile duct mixed adenoneuroendocrine carcinoma: a case report and review of the literature. Diagn Pathol. 2015;10:204. [PMID: 26589730 DOI: 10.1186/s13000-015-0439-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
69 Li T, Lv M, Chen X, Yu Y, Zang G, Tang Z. Plumbagin inhibits proliferation and induces apoptosis of hepatocellular carcinoma by downregulating the expression of SIVA. Drug Des Devel Ther 2019;13:1289-300. [PMID: 31118568 DOI: 10.2147/DDDT.S200610] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
70 Bastian K, Scott E, Elliott DJ, Munkley J. FUT8 Alpha-(1,6)-Fucosyltransferase in Cancer. Int J Mol Sci 2021;22:E455. [PMID: 33466384 DOI: 10.3390/ijms22010455] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
71 Yoo SY, Badrinath N, Woo HY, Heo J. Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. Mediators Inflamm 2017;2017:5198798. [PMID: 28512387 DOI: 10.1155/2017/5198798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
72 Li J, Liu ZY, Yu HB, Xue Q, Qu XS. Effects of oxymatrine on the proliferation of human liver cancer Bel-7404 cells: A protocol of systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e20181. [PMID: 32501970 DOI: 10.1097/MD.0000000000020181] [Reference Citation Analysis]
73 Wang N, Wang S, Li MY, Hu BG, Liu LP, Yang SL, Yang S, Gong Z, Lai PBS, Chen GG. Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies. Ther Adv Med Oncol. 2018;10:1758835918816287. [PMID: 30622654 DOI: 10.1177/1758835918816287] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 14.0] [Reference Citation Analysis]
74 Zhang Y, Yang Y, Zhang Y, Liu Z. lncRNA ST8SIA6-AS1 facilitates proliferation and invasion in liver cancer by regulating miR-142-3p. Exp Ther Med 2021;22:1348. [PMID: 34659494 DOI: 10.3892/etm.2021.10783] [Reference Citation Analysis]
75 Liu D, Staveley-O’Carroll KF, Li G. Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma. J Clin Cell Immunol. 2015;6. [PMID: 26877890 DOI: 10.4172/2155-9899.1000376] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
76 Peng P, Jia D, Cao L, Lu W, Liu X, Liang C, Pan Z, Fang Z. Akebia saponin E, as a novel PIKfyve inhibitor, induces lysosome-associated cytoplasmic vacuolation to inhibit proliferation of hepatocellular carcinoma cells. J Ethnopharmacol 2021;266:113446. [PMID: 33031902 DOI: 10.1016/j.jep.2020.113446] [Reference Citation Analysis]
77 Zheng C, Liu X, Chen L, Xu Z, Shao J. lncRNAs as prognostic molecular biomarkers in hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:59638-47. [PMID: 28938667 DOI: 10.18632/oncotarget.19559] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
78 Mohyeldeen M, Ibrahim S, Shaker O, Helmy H. Serum expression and diagnostic potential of long non-coding RNAs NEAT1 and TUG1 in viral hepatitis C and viral hepatitis C-associated hepatocellular carcinoma. Clin Biochem 2020;84:38-44. [PMID: 32526227 DOI: 10.1016/j.clinbiochem.2020.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
79 Wengert GJ, Baltzer PA, Bickel H, Thurner P, Breitenseher J, Lazar M, Pones M, Peck-radosavljevic M, Hucke F, Ba-ssalamah A. Differentiation of Intrahepatic Cholangiocellular Carcinoma from Hepatocellular Carcinoma in the Cirrhotic Liver Using Contrast-enhanced MR Imaging. Academic Radiology 2017;24:1491-500. [DOI: 10.1016/j.acra.2017.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
80 Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book 2018;38:262-79. [PMID: 30231359 DOI: 10.1200/EDBK_200939] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 20.7] [Reference Citation Analysis]
81 Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. World J Hepatol 2020; 12(9): 558-573 [PMID: 33033565 DOI: 10.4254/wjh.v12.i9.558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
82 Li Y, Li Z, Jia Y, Ding B, Yu J. In Vitro Anti-hepatoma Activities of Notoginsenoside R1 Through Downregulation of Tumor Promoter miR-21. Dig Dis Sci 2020;65:1364-75. [PMID: 31559550 DOI: 10.1007/s10620-019-05856-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
83 Shen Y, Bu L, Li R, Chen Z, Tian F, Ge Q. Expression And Biological Interaction Network Of RHOC For Hepatic Carcinoma With Metastasis In PBMC Samples. Onco Targets Ther 2019;12:9117-28. [PMID: 31806997 DOI: 10.2147/OTT.S222235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Saat TC, van den Engel S, Bijman-Lachger W, Korevaar SS, Hoogduijn MJ, IJzermans JN, de Bruin RW. Fate and Effect of Intravenously Infused Mesenchymal Stem Cells in a Mouse Model of Hepatic Ischemia Reperfusion Injury and Resection. Stem Cells Int 2016;2016:5761487. [PMID: 26981132 DOI: 10.1155/2016/5761487] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
85 Morishita A, Masaki T. MicroRNAs as possible biomarkers for hepatocellular carcinoma: MiRNAs as biomarkers for HCC. Hepatol Res 2018;48:499-501. [DOI: 10.1111/hepr.13078] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
86 Cheng L, Gao S, Song X, Dong W, Zhou H, Zhao L, Jia L. Comprehensive N-glycan profiles of hepatocellular carcinoma reveal association of fucosylation with tumor progression and regulation of FUT8 by microRNAs. Oncotarget. 2016;7:61199-61214. [PMID: 27533464 DOI: 10.18632/oncotarget.11284] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 12.0] [Reference Citation Analysis]
87 Tang Z, He J, Zou J, Yu S, Sun X, Qin L. Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC. PeerJ 2021;9:e11200. [PMID: 33954040 DOI: 10.7717/peerj.11200] [Reference Citation Analysis]
88 Wang MX, Chen D, Zhao YY, Yang B, Jiang JP, Zeng FJ, Wei L, Chen ZS. Role of selected criteria and preventive chemotherapy in tumor recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2020;19:378-83. [PMID: 32622825 DOI: 10.1016/j.hbpd.2020.06.008] [Reference Citation Analysis]
89 Zhou DD, Liu XF, Lu CW, Pant OP, Liu XD. Long non-coding RNA PVT1: Emerging biomarker in digestive system cancer. Cell Prolif. 2017;50. [PMID: 29027279 DOI: 10.1111/cpr.12398] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 9.3] [Reference Citation Analysis]
90 Zong J, Fan Z, Zhang Y. Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020;7:413-22. [PMID: 33376710 DOI: 10.2147/JHC.S272762] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Pu J, Wang J, Li W, Lu Y, Wu X, Long X, Luo C, Wei H. hsa_circ_0000092 promotes hepatocellular carcinoma progression through up-regulating HN1 expression by binding to microRNA-338-3p. J Cell Mol Med 2020. [PMID: 32077624 DOI: 10.1111/jcmm.15010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
92 Zeng Z, Dong J, Li Y, Dong Z, Liu Z, Huang J, Wang Y, Zhen Y, Lu Y. The expression level and diagnostic value of microRNA-22 in HCC patients. Artif Cells Nanomed Biotechnol. 2020;48:683-686. [PMID: 32088997 DOI: 10.1080/21691401.2019.1703723] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
93 Desai A, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. World J Hepatol 2019; 11(1): 1-18 [PMID: 30705715 DOI: 10.4254/wjh.v11.i1.1] [Cited by in Crossref: 77] [Cited by in F6Publishing: 59] [Article Influence: 38.5] [Reference Citation Analysis]
94 Meshram DD, Pike CV, Coussons PJ. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy. European Journal of Pharmacology 2017;815:332-42. [DOI: 10.1016/j.ejphar.2017.09.035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
95 Xie Y, Tian H, Xiang B, Zhang Y, Liu J, Cai Z, Xiang H. Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes. Medicine (Baltimore) 2021;100:e26958. [PMID: 34414963 DOI: 10.1097/MD.0000000000026958] [Reference Citation Analysis]
96 Demir FB, Tuncer T, Kocamaz AF, Ertam F. A survival classification method for hepatocellular carcinoma patients with chaotic Darcy optimization method based feature selection. Med Hypotheses 2020;139:109626. [PMID: 32087492 DOI: 10.1016/j.mehy.2020.109626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
97 Cruz-Ramón V, Chinchilla-López P, Ramírez-Pérez O, Qi X, Méndez-Sánchez N. The Changing Face of the Diagnosis of Chronic and Malignant Liver Diseases: Potential New Biomarkers. Ann Hepatol 2018;17:14-7. [PMID: 29311406 DOI: 10.5604/01.3001.0010.7531] [Reference Citation Analysis]
98 Akazawa Y, Suzuki T, Yoshikawa T, Mizuno S, Nakamoto Y, Nakatsura T. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World J Meta-Anal 2019; 7(3): 80-95 [DOI: 10.13105/wjma.v7.i3.80] [Reference Citation Analysis]
99 Liu J, Huang L, Zhu Y, He Y, Zhang W, Lei T, Xuan J, Xiao B, Li L, Zhou Q, Sun Z. Exploring the Expression and Prognostic Value of the TCP1 Ring Complex in Hepatocellular Carcinoma and Overexpressing Its Subunit 5 Promotes HCC Tumorigenesis. Front Oncol 2021;11:739660. [PMID: 34676169 DOI: 10.3389/fonc.2021.739660] [Reference Citation Analysis]
100 Saha SK, Yin Y, Kim K, Yang GM, Dayem AA, Choi HY, Cho SG. Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells. Int J Mol Sci 2017;18:E1048. [PMID: 28498322 DOI: 10.3390/ijms18051048] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
101 Luo X, Yang S, Zhou C, Pan F, Li Q, Ma S. MicroRNA-328 enhances cellular motility through posttranscriptional regulation of PTPRJ in human hepatocellular carcinoma. Onco Targets Ther 2015;8:3159-67. [PMID: 26604785 DOI: 10.2147/OTT.S93056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
102 Zhou C, Chen Z, Peng C, Chen C, Li H. Long Noncoding RNA TRIM52-AS1 Sponges miR-514a-5p to Facilitate Hepatocellular Carcinoma Progression Through Increasing MRPS18A. Cancer Biother Radiopharm 2021;36:211-9. [PMID: 32391716 DOI: 10.1089/cbr.2019.3271] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
103 Zhang R, Lin P, Yang H, He Y, Dang YW, Feng ZB, Chen G. Clinical role and biological function of CDK5 in hepatocellular carcinoma: A study based on immunohistochemistry, RNA-seq and in vitro investigation. Oncotarget 2017;8:108333-54. [PMID: 29312535 DOI: 10.18632/oncotarget.22659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
104 Liu K, Zhang Y, Zhang C, Zhang Q, Li J, Xiao F, Li Y, Zhang R, Dou D, Liang J, Qin J, Lin Z, Zhao D, Jiang M, Liang Z, Su J, Gupta VP, He M, Yang X. Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma. Oncotarget 2016;7:56798-810. [PMID: 27462864 DOI: 10.18632/oncotarget.10792] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
105 Abbastabar M, Sarfi M, Golestani A, Khalili E. lncRNA involvement in hepatocellular carcinoma metastasis and prognosis. EXCLI J 2018;17:900-13. [PMID: 30564069 DOI: 10.17179/excli2018-1541] [Cited by in F6Publishing: 49] [Reference Citation Analysis]
106 Zhu D, Qin Y, Wang J, Zhang L, Zou S, Zhu X, Zhu L. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging. Bioconjugate Chem 2016;27:831-9. [DOI: 10.1021/acs.bioconjchem.6b00030] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
107 Zheng A, Zhang X, Gao J, Liu X, Liu J. Peroxidase-like catalytic activity of copper ions and its application for highly sensitive detection of glypican-3. Analytica Chimica Acta 2016;941:87-93. [DOI: 10.1016/j.aca.2016.08.036] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
108 Wu S, Ai H, Zhang K, Yun H, Xie F. Long Non-Coding RNA EGOT Promotes the Malignant Phenotypes of Hepatocellular Carcinoma Cells and Increases the Expression of HMGA2 via Down-Regulating miR-33a-5p. Onco Targets Ther 2019;12:11623-35. [PMID: 32021242 DOI: 10.2147/OTT.S218308] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
109 Zhao H, Zhang Y, Sun J, Zhan C, Zhao L. Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest. Oncol Res 2016;23:237-48. [PMID: 27098147 DOI: 10.3727/096504016X14562725373671] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
110 Yin Z, Ma T, Lin Y, Lu X, Zhang C, Chen S, Jian Z. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma. J Cell Biochem. 2018;119:9419-9432. [PMID: 30015355 DOI: 10.1002/jcb.27259] [Cited by in Crossref: 67] [Cited by in F6Publishing: 77] [Article Influence: 22.3] [Reference Citation Analysis]
111 Zheng K, Liao C, Li Y, Fan X, Fan L, Xu H, Kang Q, Zeng Y, Wu X, Wu H, Liu L, Xiao X, Zhang J, Wang Y, He Z. Gypenoside L, Isolated from Gynostemma pentaphyllum , Induces Cytoplasmic Vacuolation Death in Hepatocellular Carcinoma Cells through Reactive-Oxygen-Species-Mediated Unfolded Protein Response. J Agric Food Chem 2016;64:1702-11. [DOI: 10.1021/acs.jafc.5b05668] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
112 Omar M, Farid K, Emran T, El-Taweel F, Tabll A, Omran M. HCC-Mark: a simple non-invasive model based on routine parameters for predicting hepatitis C virus related hepatocellular carcinoma. Br J Biomed Sci 2021;78:72-7. [PMID: 33016838 DOI: 10.1080/09674845.2020.1832371] [Reference Citation Analysis]
113 Simon J, Ouro A, Ala-Ibanibo L, Presa N, Delgado TC, Martínez-Chantar ML. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover. Int J Mol Sci 2019;21:E40. [PMID: 31861664 DOI: 10.3390/ijms21010040] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
114 Sacco R, Antonucci M, Bresci G, Corti A, Giacomelli L, Mismas V, Rainieri M, Romano A, Eggenhoffner R, Tumino E, Cabibbo G. Curative therapies for hepatocellular carcinoma: an update and perspectives. Expert Review of Anticancer Therapy 2016;16:169-75. [DOI: 10.1586/14737140.2016.1123625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]